Home » Vermillion Awarded FDA Clearance for Overa
Vermillion Awarded FDA Clearance for Overa
Austin, Texas-based Vermillion has earned FDA clearance for its blood test Overa — dubbed a successor to its OVA1 — for identifying ovarian cancer risk.
The test is intended for use in combination with clinical and imaging assessment before surgery in women with a pelvic mass, the company says.
Overa operates on a Roche Cobas 6000 platform. Further, it swaps two biomarkers from the original test out for human epididymal protein 4 and a follicle stimulating hormone to enhance specificity and minimize the need to determine menopausal status. — Anisa Jibrell
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May